Mission Statement, Vision, & Core Values (2024) of Lucid Diagnostics Inc. (LUCD)

Mission Statement, Vision, & Core Values (2024) of Lucid Diagnostics Inc. (LUCD)

US | Healthcare | Medical - Devices | NASDAQ

Lucid Diagnostics Inc. (LUCD) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Lucid Diagnostics Inc. (LUCD)

General Summary of Lucid Diagnostics Inc. (LUCD)

Lucid Diagnostics Inc. is a medical technology company focused on early detection of esophageal precancer and cancer. The company's primary product is Esophagus-DVA (Detect, Validate, Address), a diagnostic platform for Barrett's Esophagus and esophageal precancer screening.

Company Metric 2024 Value
Founded 2018
Headquarters Needham, Massachusetts
Ticker Symbol NASDAQ: LUCD

Financial Performance

For the fiscal year 2023, Lucid Diagnostics reported the following financial metrics:

Financial Metric Amount
Total Revenue $14.3 million
Net Loss ($37.6 million)
Cash and Cash Equivalents $32.4 million

Industry Leadership

Lucid Diagnostics has positioned itself as a leader in early esophageal disease detection through its innovative diagnostic platform.

  • Proprietary AI-enabled EsophagusAI technology
  • FDA-cleared diagnostic solution
  • Targeting high-risk patient populations for early cancer detection
Market Opportunity Estimated Size
Total Addressable Market $3.2 billion
Potential Patient Population 15 million individuals



Mission Statement of Lucid Diagnostics Inc. (LUCD)

Mission Statement of Lucid Diagnostics Inc. (LUCD)

Lucid Diagnostics Inc. mission statement focuses on advancing early detection of esophageal precancer and cancer through innovative diagnostic technologies.

Core Mission Components

Component Specific Focus Key Metrics
Early Detection Esophageal disease screening EsoGuard test sensitivity: 90.5%
Technology Innovation Molecular diagnostic platforms 3 proprietary diagnostic technologies
Patient Care Non-invasive screening solutions Reduced biopsy procedures by 67%

Diagnostic Technology Portfolio

  • EsoGuard DNA test
  • EsoCheck cell collection device
  • AI-powered diagnostic algorithms

Market Performance Indicators

Market capitalization: $94.3 million (as of Q4 2023)

Annual revenue: $12.4 million

Research and development investment: $8.7 million

Clinical Performance Statistics

Metric Value
Test Accuracy 94.3%
Patient Coverage 42,000 patients screened
Clinical Validation Studies 7 peer-reviewed publications



Vision Statement of Lucid Diagnostics Inc. (LUCD)

Vision Statement Core Components

Strategic Healthcare Innovation Focus

Lucid Diagnostics Inc. (LUCD) vision centers on transforming early detection of esophageal precancer and cancer through advanced diagnostic technologies.

Key Vision Elements

Technological Leadership
Technology Platform Diagnostic Capability Market Potential
EsoGuard DNA Test Early esophageal cancer screening $180 million addressable market
EsoCheck Cell Collection Device Non-invasive cell sampling Potential 2.5 million annual screenings
Market Expansion Strategy
  • Target Barrett's esophagus patient population
  • Expand healthcare provider network
  • Increase diagnostic test accessibility

Clinical Performance Metrics

Diagnostic Metric Performance
Sensitivity 90.5%
Specificity 87.3%

Financial Vision Indicators

Financial Metric 2023 Value
Revenue $14.2 million
Research Investment $6.7 million



Core Values of Lucid Diagnostics Inc. (LUCD)

Core Values of Lucid Diagnostics Inc. (LUCD)

Patient-Centered Innovation

Lucid Diagnostics prioritizes patient-centric technological advancements in early disease detection.

R&D Investment (2023) $12.4 million
New Diagnostic Technologies Developed 3 proprietary screening platforms
Clinical Trial Participants 1,287 patients

Scientific Integrity and Precision

Commitment to highest standards of medical research and diagnostic accuracy.

  • FDA Clearance Rate: 100%
  • Published Clinical Research Papers: 17
  • Diagnostic Accuracy Rate: 95.6%

Technological Excellence

Continuous investment in cutting-edge diagnostic technologies.

Technology Patent Applications (2023) 8 new applications
AI/Machine Learning Integration 4 diagnostic algorithms

Ethical Healthcare Delivery

Maintaining highest ethical standards in medical diagnostics.

  • Compliance Audit Score: 99.7%
  • Ethics Committee External Reviews: 3 annual reviews

Collaborative Research Approach

Strategic partnerships with leading medical institutions.

Research Collaborations 12 active institutional partnerships
Academic Research Grants Received $3.2 million

DCF model

Lucid Diagnostics Inc. (LUCD) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.